Metabolic interactions between glutamatergic and dopaminergic neurotransmitter systems are mediated through D1 dopamine receptors

Journal of Neuroscience Research

Volumn 85, Issue 15, 2007, Pages 3284-3293

  Rodrigues, Tiago B ^a,b   Granado, Noelia ^c   Ortiz, Oskar ^c   Cerdán, Sebastián ^a   Moratalla, Rosario ^c  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c INSTITUTO CAJAL   (Spain)

Author keywords

13C NMR; Dopamine; Dopamine D1 and D2 receptors; Glutamate; Parkinson's disease, striatum

Indexed keywords

DOPAMINE 1 RECEPTOR; GLUTAMIC ACID; GLUTAMINE; LEVODOPA;

CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; METABOLIC REGULATION; MOUSE; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

ANIMALS; BRAIN; DOPAMINE; GLUTAMIC ACID; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, DOPAMINE D1;

EID: 35848961005     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21302     Document Type: Conference Paper

References (58)

1. 1 dopamine receptor activation reduces extracellular glutamate and GABA concentrations in the medial prefrontal cortex. Brain Res 867:250-254.
2. 2 receptors. Nature 377:424-428.
3. 1H NMR study. J Biol Chem 273:27162-27169.
4. Carlsson A, Lindqvist M, Magnusson T. 1957. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200.
5. 1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 23:8506-8512.
6. 13C NMR. J Biol Chem 265:12916-12926.
7. 13C nuclear magnetic resonance. Endocrinology 136:296-305.
8. Chase TN, Oh JD. 2000. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23:S86-S91.
9. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19:9192-9200.
10. Chen L, Zhuang X. 2003. Transgenic mouse models of dopamine deficiency. Ann Neurol 54:S91-S102.
11. Conn PJ. 2003. Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann N Y Acad Sci 1003:12-21.
12. Coyle JT. 2006. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26:363-382.
13. 13C NMR studies of metabolic compartmentation in the adult mammalian brain. NMR Biomed 12:451-462.
14. 2-like, dopamine receptors in the rat nucleus accumbens. Eur J Neurosci 13:2157-2164.
15. Day M, Wang Z, Ding J, An X, Ingham CA, Shering AF, Wokosin D, Ilijic E, Sun Z, Sampson AR, Mugnaini E, Deutch AY, Sesack SR, Arbuthnott GW, Surmeier DJ. 2006. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9:251-259.
16. de Bartolomeis A, Fiore G, Iasevoli F. 2005. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr Pharm Des 11:3561-3594.
17. 13C NMR spectroscopy. Neurochem Int 45:297-303.
18. 1 but not D5 dopamine receptors are critical for LTP, spatial learning and LTP-induced arc and zif268 expression in the hippocampus. Cereb Cortex (in press).
19. Grande C, Zhu H, Martin AB, Lee M, Ortiz O, Hiroi N, Moratalla R. 2004. Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats. Biol Psychiatry 55:457-463.
20. Graybiel AM, Moratalla R, Robertson HA. 1990. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci U S A 87:6912-6916.
21. Hiroi N, Martin AB, Grande C, Alberti I, Rivera A, Moratalla R. 2002. Molecular dissection of dopamine receptor signaling. J Chem Neuroanat 23:237-242.
22. Hornykiewicz O. 2002. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23:65-70.
23. Jonkers N, Sarre S, Ebinger G, Michotte Y. 2002. MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res 926:149-155.
24. Kalivas PW, McFarland K, Bowers S, Szumlinski K, Xi ZX, Baker D. 2003. Glutamate transmission and addiction to cocaine. Ann N Y Acad Sci 1003:169-175.
25. Karasawa J, Yoshimizu T, Chaki S. 2006. A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neurosci Lett 393:127-130.
26. Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhart-Kasch S, Zhang G, Bunzow JR, Fang Y, Gerhardt GA, Grandy DK, Low MJ. 1998. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 18:3470-3479.
27. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. 2002. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7:S71-S80.
28. 2 synergism are unrelated to changes in striatal receptor density. Synapse 12:14-26.
29. Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB Jr, Young AB. 1995. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 15:5297-5307.
30. Lange KW, Kornhuber J, Riederer P. 1997. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 21:393-400.
31. Lapish CC, Seamans JK, Judson Chandler L. 2006. Glutamate-dopamine cotransmission and reward processing in addiction. Alcohol Clin Exp Res 30:1451-1465.
32. 13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. J Neurosci 22:1523-1531.
33. 1 receptor. Cell 111:219-230.
34. 13C magnetic resonance spectroscopy study. Magma 16:29-42.
35. Lipsky RH, Goldman D. 2003. Genomics and variation of ionotropic glutamate receptors. Ann N Y Acad Sci 1003:22-35.
36. Malenka RC. 2003. Synaptic plasticity and AMPA receptor trafficking. Ann N Y Acad Sci 1003:1-11.
37. Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, Buckman JF. 1999. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88:1-16.
38. Moratalla R, Elibol B, Vallejo M, Graybiel AM. 1996a. Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal. Neuron 17:147-156.
39. 1 dopamine receptor. Proc Natl Acad Sci U S A 93:14928-14933.
40. Pascual JM, Carceller F, Roda JM, Cerdan S. 1998. Glutamate, glutamine, and GABA as substrates for the neuronal and glial compartments after focal cerebral ischemia in rats. Stroke 29:1048-1056; discussion 1056-1057.
41. Pavon N, Martin AB, Mendialdua A, Moratalla R. 2006. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59:64-74.
42. 1 receptor function by physical interaction with the NMDA receptors. J Neurosci 24:1149-1158.
43. Rivera A, Cuellar B, Giron FJ, Grandy DK, de la Calle A, Moratalla R. 2002. Dopamine D4 receptors are heterogeneously distributed in the striosomes/matrix compartments of the striatum. J Neurochem 80:219-229.
44. 13C MRS: an outstanding tool for metabolic studies. Concepts Magnet Reson 27A:1-16.
45. 13C MRS in vivo. NMR Biomed 16:358-369.
46. Rothman DL, Behar KL, Hyder F, Shulman RG. 2003. In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev Physiol 65:401-427.
47. 1 and NMDA receptors hook up: expanding on an emerging theme. Trends Neurosci 26:235-237.
48. Sanacora G, Rothman DL, Mason G, Krystal JH. 2003. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci 1003:292-308.
49. Schildkraut JJ, Gordon EK, Durell J. 1965. Catecholamine metabolism in affective disorders. I. Normetanephrine and VMA excretion in depressed patients treated with Imipramine. J Psychiatr Res 3:213-228.
50. Sesack SR, Carr DB, Omelchenko N, Pinto A. 2003. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann N Y Acad Sci 1003:36-52.
51. Slattery DA, Hudson AL, Nutt DJ. 2004. Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol 18:1-21.
52. Smith WB, Starck SR, Roberts RW, Schuman EM. 2005. Dopaminergic Stimulation of local protein synthesis enhances surface expression of GluR1 and synaptic transmission in hippocampal neurons. Neuron 45:765-779.
53. Tamminga CA, Lahti AC, Medoff DR, Gao XM, Holcomb HH. 2003. Evaluating glutamatergic transmission in schizophrenia. Ann N Y Acad Sci 1003:113-118.
54. Waagepetersen HS, Sonnewald U, Larsson OM, Schousboe A. 2001. Multiple compartments with different metabolic characteristics are involved in biosynthesis of intracellular and released glutamine and citrate in astrocytes. Glia 35:246-252.
55. Waniewski RA, Martin DL. 1998. Preferential utilization of acetate by astrocytes is attributable to transport. J Neurosci 18:5225-5233.
56. West AR, Floresco SB, Charara A, Rosenkranz JA, Grace AA. 2003. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann N Y Acad Sci 1003:53-74.
57. 1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79:729-742.
58. Yamamoto BK, Davy S. 1992. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J Neurochem 58:1736-1742.